热门标签

Sanofi ends cancer drug trials

时间:1个月前   阅读:2

新加坡telegram群组www.tg888.vip)是一个Telegram群组分享平台,飞机群组内容包括telegram群组索引、Telegram群组导航、新加坡telegram群组、telegram中文群组、telegram群组(其他)、Telegram 美国 群组、telegram群组爬虫、电报群 科学上网、小飞机 怎么 加 群、tg群等内容,为广大电报用户提供各种电报群组/电报频道/电报机器人导航服务。

The decision to stop all studies with amcenestrant follows an analysis of late-stage trial data evaluating the drug in patients with a type of breast cancer, the company said in a statement yesterday.

PARIS: Sanofi is ending development of a key cancer medicine in a blow to the French drugmaker’s pipeline of experimental therapies.

The decision to stop all studies with amcenestrant follows an analysis of late-stage trial data evaluating the drug in patients with a type of breast cancer, the company said in a statement yesterday.

The move leaves Sanofi even more dependent for growth on blockbuster Dupixent, an antibody treatment for ailments ranging from asthma to severe eczema.

The company’s slate of experimental medicines has faced other setbacks, including safety concerns regarding multiple sclerosis treatment tolebrutinib.

,

皇冠信用网appwww.hg108.vip)是一个开放皇冠信用网代理APP下载、皇冠信用网会员APP下载、皇冠信用网线路APP下载、皇冠信用网登录APP下载的皇冠正网平台。皇冠信用网APP上最新登录线路、新2皇冠信用网更新最快。皇冠信用网APP开放皇冠信用网会员注册、皇冠信用网代理开户等业务。

,

Sanofi has included both amcenestrant and tolebrutinib as among six products in its pipeline that it prioritised as “potentially transformative” treatments.

Some investors are questioning the company’s growth trajectory after both of those medicines encountered problems.

UBS analysts last week downgraded Sanofi, saying there are few major catalysts coming soon to drive more excitement to the stock. — Bloomberg


转载说明:本文转载自Sunbet。

上一篇:以太坊单双博彩(www.eth108.vip):Trading ideas: Carlsberg, Pharmaniaga, Sentral REIT, AirAsia X, Inari Amertron, Hong Leong Industries, TCS, Advancecon, Tenaga, UEM Sunrise and Sapura Energy

下一篇:皇冠管理端登3手机(www.99cx.vip):Smaller net loss for Pos Malaysia in 2Q

网友评论